Abstract

Triple-negative breast cancer (TNBC) represents a particularly aggressive subtype of breast cancer, characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression. The lack of targeted therapies for TNBC underscores the urgent need for effective treatment strategies. Immunotherapy has emerged as a promising approach for TNBC, with the immune checkpoint inhibitor Tislelizumab showing encouraging results in combination with chemotherapy. This article reviews the rationale, clinical evidence, and future prospects of Tislelizumab plus chemotherapy for advanced TNBC.